Screener
Opus Genetics IRD Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 10,577 | 7,953 |
| General and administrative | 5,944 | 6,346 |
| Total operating expenses | 16,521 | 14,299 |
| Loss from operations | (14,364) | (9,929) |
| Fair value change in warrant liabilities | (51,364) | 2,805 |
| Financing costs | (582) | (1,372) |
| Interest expense | (69) | — |
| Other income, net | 844 | 302 |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's operating income?
- Opus Genetics (IRD) reported operating income of -$14.36M in Q1 2026.
- How has Opus Genetics's operating income changed year-over-year?
- Opus Genetics's operating income decreased by 44.7% year-over-year, from -$9.93M to -$14.36M.
- What is the long-term trend for Opus Genetics's operating income?
- Over 4 years (2021 to 2025), Opus Genetics's operating income has grown at a 14.2% compound annual growth rate (CAGR), from -$22.71M to -$38.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Opus Genetics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude